Managing Constipation on Wegovy (semaglutide 2.4 mg): The HealthRX.com Step-by-Step Protocol

How often does constipation occur on Wegovy 2.4 mg?

The label reports constipation in 24% of adults taking the 2.4 mg weekly injection and 11% of adults on placebo. Those numbers come from three randomized, double-blind, placebo-controlled trials in 2,116 adults with obesity or overweight and 1,261 adults on placebo, treated for up to 68 weeks [1].

Constipation is among Wegovy's most common adverse reactions, which the label defines as reactions seen in at least 5% of patients. In the same trials, 73% of people on 2.4 mg had at least one gastrointestinal reaction, against 47% on placebo [1].

Which serious events does the label list?

Severe gastrointestinal adverse reactions were reported in 4.1% of adults on Wegovy 2.4 mg and 0.9% of adults on placebo [1]. Reports received after marketing include ileus, intestinal obstruction and severe constipation with fecal impaction; the label says frequency cannot be estimated from voluntary reports [1].

The pancreatitis warning describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Wegovy if pancreatitis is suspected [1].

Does Wegovy affect how fast the stomach empties?

The label states that Wegovy delays gastric emptying and that it is not recommended in patients with severe gastroparesis, a condition in which the stomach empties slowly. The label does not state that Wegovy causes gastroparesis [1].

Does the label give a plan for treating constipation?

No. Wegovy's label describes constipation as an adverse reaction and records the serious bowel events above, but it sets out no fiber target, fluid volume, stool softener, osmotic or stimulant laxative, prokinetic drug, dose hold or step-up schedule for constipation [1].